Related Experiment Video

Updated: Aug 26, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.9K

Delta and Notch-like epidermal growth factor-related receptor suppresses human glioma growth by inhibiting oncogene

Qun Wang1, Yaqiong Li2, Jiamei Li2

  • 1Department of Ophthalmology, The 4th People's Hospital of Jinan, Jinan, Shandong, China.

Journal of Cancer Research and Therapeutics
|October 7, 2022
PubMed

Insights

Delta and Notch-like endothelial growth factor-related receptor (DNER) suppresses glioma growth by inhibiting the oncogene Torsin family 4 member A (TOR4A). DNER acts as a tumor suppressor by reducing TOR4A-driven cell proliferation and promoting apoptosis.

Area of Science:

  • Neuroscience
  • Oncology
  • Molecular Biology

Background:

  • Delta and Notch-like endothelial growth factor-related receptor (DNER) is a transmembrane protein involved in neuron-glia communication.
  • Gliomas are primary brain tumors with significant morbidity and mortality.
  • Understanding DNER's role in glioma pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To elucidate the mechanism by which DNER inhibits human glioma growth.
  • To investigate the role of Torsin family 4 member A (TOR4A) in DNER-mediated glioma suppression.
  • To identify DNER and TOR4A as potential therapeutic targets for glioma treatment.

Main Methods:

  • RNA sequencing to identify differentially expressed genes post-DNER inhibition.
  • Functional assays including cell proliferation, clonogenic, migration, and invasion assays.
  • In vivo glioma transplantation models and analysis of human glioma tissue data (Chinese Glioma Genome Atlas).
  • Western blot analysis for protein expression.

Main Results:

  • DNER inhibition led to increased TOR4A expression in glioma cells.
  • High TOR4A expression correlated with poor patient prognosis.
  • TOR4A promoted glioma cell proliferation and inhibited apoptosis, partly via enhancing p-AKT and reducing antiapoptotic proteins.
  • DNER suppressed glioma growth by inhibiting TOR4A activity.

Conclusions:

  • TOR4A functions as an oncogene promoting glioma progression.
  • DNER acts as a tumor suppressor gene by inhibiting TOR4A.
  • Targeting the DNER-TOR4A pathway may offer a novel therapeutic strategy for gliomas.
Keywords:
DNERTOR4Agliomagrowthoncogene

More Related Videos

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

23.2K
Three-Dimensional 3D Tumor Spheroid Invasion Assay12:19

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Published on: May 1, 2015

57.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
4.4K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K